BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $12.00 Price Target at Evercore ISI

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target boosted by Evercore ISI from $10.00 to $12.00 in a report released on Monday,Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the stock. Needham & Company LLC lifted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.23 on Monday. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The stock’s 50-day simple moving average is $7.59 and its 200-day simple moving average is $7.61. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -11.85 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% compared to the same quarter last year. As a group, research analysts predict that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its position in shares of BioCryst Pharmaceuticals by 6.3% during the second quarter. Rhumbline Advisers now owns 318,665 shares of the biotechnology company’s stock worth $1,969,000 after acquiring an additional 18,916 shares during the last quarter. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at about $104,000. American Century Companies Inc. grew its position in BioCryst Pharmaceuticals by 896.6% in the 2nd quarter. American Century Companies Inc. now owns 148,490 shares of the biotechnology company’s stock worth $918,000 after purchasing an additional 133,591 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of BioCryst Pharmaceuticals by 32.7% in the second quarter. Hsbc Holdings PLC now owns 125,004 shares of the biotechnology company’s stock valued at $759,000 after purchasing an additional 30,788 shares during the period. Finally, Seven Eight Capital LP raised its holdings in shares of BioCryst Pharmaceuticals by 1,407.1% during the second quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after buying an additional 158,358 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.